US Stock MarketDetailed Quotes
AKTX Akari Therapeutics
Watchlist
3.2300
+0.2800+9.49% Close 12/01 16:00 ET
3.23000.00000.00%
Post 16:00 ET
3.3734High2.9300Low9.29KVolume
2.9300Open2.9500Pre Close29.45KTurnover0.25%Turnover RatioLossP/E (TTM)18.26MMarket Cap12.000052wk HighLossP/E (Static)5.65MShares2.808052wk Low6.57P/B11.88MFloat Cap5000.0000Historical High--Dividend TTM3.68MShs Float2.8000Historical Low--Div YieldTTM15.03%Amplitude3.1700Avg Price1Lot Size
About Akari Therapeutics Company
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
Company Profile
SymbolAKTX
Company NameAkari Therapeutics
Listing Date01/31/2014
Founded2004
CEOMs. Rachelle Jacques
MarketNASDAQ
Employees15
Securities TypeDR
ADS Ratio1.0 : 2000.0
Fiscal Year Ends12-31
Address75/76 Wimpole Street
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW1G 9RT
Phone44-20-8004-0261
Websitehttp://www.akaritx.com
Company Executives
- Name
- Position
- Salary
- Rachelle Jacques
- Director, President and Chief Executive Officer
- 3.60M
- Dr. Torsten Hombeck, PhD
- Chief Financial Officer
- 448.75K
- Melissa Bradford Klug
- Chief Operating Officer
- --
- Dr. John F. Neylan, M.D.
- Chief Medical Officer
- --
- Dr. Miles Nunn
- Chief Scientific Officer
- --
- Ray Prudo, M.D.
- Executive Chairman of the Board
- 618.00K
- Dr. James Ferguson Hill, M.D.
- Independent Director
- 81.78K
- Donald A. Williams
- Independent Director
- 77.12K
- Dr. Stuart Ungar, M.D.
- Independent Director
- 69.34K
- David Byrne
- Independent Director
- 78.61K
- Michael Grissinger
- Independent Director
- 61.78K